Information  X 
Enter a valid email address

Oxford Biomedica PLC Ord 1P (OXB)

Related News

28-May-2021 07:49 AM

Oxford Biomedica announces all resolutions passed at AGM

All 19 resolutions at Oxford Biomedica were passed by shareholders at the company's AGM on 27 May, including a new directors' remuneration policy. Some 80.94% of shareholders voted to replace the directors' remuneration policy approved in
27-May-2021 07:12 AM

Oxford Biomedia non-exec retires after 11 years on the board

Oxford Biomedica has confirmed that Andrew Heath will be retiring from the board as non executive director following the annual general meeting being held on Thursday 27 May. Heath joined the board in January 2010 and became deputy chair and senior inde
18-May-2021 07:06 AM

Oxford Biomedica ups earnings guidance as AstraZeneca increases vaccine order

Gene and cell therapy group Oxford Biomedica upgraded its annual earnings guidance after AstraZeneca increased the size of an order related to Covid-19 vaccines. Oxford Biomedica had in September signed an 18-month supply agreement with AstraZeneca for
15-Apr-2021 07:44 AM

Oxford Biomedica sees revenue boost following Covid-19 vaccine response

Cell and gene therapy group, Oxford Biomedica, has seen total revenues increase by 37% to £87.7 million in the year ending 31 December 2020. Bioprocessing and commercial development revenues increased by 45% to £68.5 million (2019: £47
03-Feb-2021 01:38 PM

Oxford Biomedica boost board

Oxford Biomedia has added a new non-executive director to its board, with Professor Dame Kay Davies joining on 1st March 2021. Professor Davies is a world-leading human geneticist with a research focus on the molecular analysis of neuromuscular and neuro
09-Nov-2020 07:47 AM

Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration

Gene therapy group Oxford Biomedica and biopharmaceutical company PhoreMost have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. PhoreMost will use its in-house expertise and next-generation phenotypic screening p
17-Sep-2020 07:35 AM

Revenue, cash up for Oxford Biometrica as work starts on COVID-19 vaccine

Biotech company Oxford Biomedica increased its revenue in the first half of 2020 by 6%, it announced this morning. Bioprocessing and commercial development were particularly strong, posting revenues of £23.4m, up by 24%. The company recorded an op
24-Jun-2020 08:00 AM

Broker Forecast - Liberum Capital issues a broker note on Oxford BioMedica PLC

Liberum Capital today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and cut its price target to 1050p (from 1090p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
22-Jun-2020 08:40 AM

Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC

Peel Hunt today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and cut its price target to 1000p (from 1050p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
11-Jun-2020 08:20 AM

Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC

Peel Hunt today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and cut its price target to 1050p (from 1060p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
14-May-2020 01:30 PM

Broker Forecast - Jefferies International issues a broker note on Oxford BioMedica PLC

Jefferies International today reaffirms its hold investment rating on Oxford BioMedica PLC (LON:OXB) and raised its price target to 730p (from 700p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
06-May-2020 09:20 AM

Oxford Biomedica swings to loss as milestone revenue falls

Gene and cell therapy group Oxford Biomedica swung to a full-year loss, owing to a rise in expenses and fall in revenue. Pre-tax losses for the year through December amounted to £20.9m, compared to a profit of £5.0m on-year. Revenue fell 4%
28-Apr-2020 11:20 AM

Broker Forecast - Liberum Capital issues a broker note on Oxford BioMedica PLC

Liberum Capital today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and raised its price target to 1090p (from 860p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
13-Jan-2020 10:50 AM

Broker Forecast - Liberum Capital issues a broker note on Oxford BioMedica PLC

Liberum Capital today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and raised its price target to 860p (from 810p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
04-Sep-2019 07:39 AM

Oxford Biomedica losses deepen as sales fall, R&D costs rise

Gene and cell therapy company Oxford Biomedica booked a deeper first-half loss, after sales fell and it upped spending on R&D. Pre-tax losses for the six months through June amounted to £12.1m, compared to a profit of £5.2m on-year. Revenues
28-May-2019 08:00 AM

Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC

Peel Hunt today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and raised its price target to 1060p (from 1010p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
15-Mar-2019 08:10 AM

Broker Forecast - Jefferies International issues a broker note on Oxford BioMedica PLC

Jefferies International today reaffirms its hold investment rating on Oxford BioMedica PLC (LON:OXB) and cut its price target to 725p (from 800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
04-Jan-2019 08:10 AM

Broker Forecast - Jefferies International issues a broker note on Oxford BioMedica PLC

Jefferies International today reaffirms its hold investment rating on Oxford BioMedica PLC (LON:OXB) and cut its price target to 800p (from 1100p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
13-Sep-2018 08:27 AM

Oxford BioMedica sees 118% jump in gross income, expands bioprocessing capacity

Gene and cell therapy group Oxford BioMedica reported an operating profit of £9.4m for the first half of 2018, compared with a £2.2m loss a year earlier, while gross income jumped 118% to £36m, driven by £20.6 million worth of lice
13-Jun-2018 08:40 AM

Broker Forecast - Jefferies International issues a broker note on Oxford BioMedica PLC

Jefferies International today downgrades its investment rating on Oxford BioMedica PLC (LON:OXB) to hold (from buy) and raised its price target to 1100p (from 825p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmaga
06-Jun-2018 08:40 AM

Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC

Peel Hunt today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and raised its price target to 1010p (from 780p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
02-May-2018 12:40 PM

Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC

Peel Hunt today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and set its price target at 16p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
09-Apr-2018 09:50 AM

Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC

Peel Hunt today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and set its price target at 16p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
15-Mar-2018 09:20 AM

Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC

Peel Hunt today reaffirms its buy investment rating on Oxford BioMedica PLC (LON:OXB) and raised its price target to 16p (from 13p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
15-Mar-2018 08:38 AM

Oxford BioMedica cuts EBITDA loss

Oxford BioMedica, a gene and cell therapy group, increased its gross income by 28% to £39.4 million in the year to 31 December 2017. Operating expenses excluding depreciation and amortisation and share based payments decreased by 12% to £22.9
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t